Cargando…
Seroconversion after anti‐SARS‐CoV‐2 mRNA vaccinations among moderate‐to‐severe psoriatic patients receiving systemic biologicals—Prospective observational cohort study
It is unclear whether biological antipsoriatic therapies affect seroconversion after messenger ribonucleic acid (mRNA)‐based antisevere acute respiratory syndrome coronavirus 2 (anti‐SARS‐CoV‐2) vaccinations. To assess antibody formation and the incidence of side effects after anti‐SARS‐CoV‐2 mRNA v...
Autores principales: | Piros, Éva Anna, Cseprekál, Orsolya, Görög, Anna, Hidvégi, Bernadett, Medvecz, Márta, Szabó, Zsófia, Olajos, Ferenc, Barabás, Eszter, Galajda, Noémi, Miheller, Pál, Holló, Péter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9111760/ https://www.ncbi.nlm.nih.gov/pubmed/35218276 http://dx.doi.org/10.1111/dth.15408 |
Ejemplares similares
-
381 Seroconversion after anti-SARS-CoV-2 mRNA vaccinations among moderate-to-severe psoriatic patients receiving systemic biologicals
por: Piros, É.A., et al.
Publicado: (2022) -
EP1270: SEROCONVERSION IN INFLAMMATORY BOWEL DISEASE PATIENTS AFTER COVID-19 VACCINATION
por: Horvath, Miklos, et al.
Publicado: (2022) -
Anti-Interleukin-17 Therapy of Severe Psoriatic Patients Results in an Improvement of Serum Lipid and Inflammatory Parameters’ Levels, but Has No Effect on Body Composition Parameters
por: Piros, Éva Anna, et al.
Publicado: (2021) -
Impact of Interleukin-17 Inhibitor Therapy on Arterial Intima-media Thickness among Severe Psoriatic Patients
por: Piros, Éva Anna, et al.
Publicado: (2021) -
Immunohistochemical Study of the PD-1/PD-L1 Pathway in Cutaneous Lupus Erythematosus
por: Király, Zsófia, et al.
Publicado: (2022)